ABU DHABI 31 March, 2017: Julphar Gulf Pharmaceutical Industries has expressed its intention to develop and expand in more than 34 countries around the world, consolidating its prominent position in the global pharmaceutical industry.
Dr Hosam Badr, Marketing Director at Julphar, said on the sidelines of the Global Manufacturing & Industrialisation Summit (GMIS), that Julphar plans to expand and enter new markets.
A Julphar factory in Saudi Arabia will be opened soon, as well as the factories in Bangladesh and Ethiopia, in addition to projects in Morocco, Algeria and Egypt, where medicines are being manufactured locally, he told Emirates News Agency (Wam).
The company’s expansion plans include 34 countries around the world, and it plans to export more than 90 per cent of its products. Julphar is considered among the leading companies that exports to countries such Saudi Arabia, which is the biggest market for the company in the region, as well as Kuwait, Omar, Yemen, Iraq and Lebanon, he remarked.
The company is now focussing on the development of the insulin project. It has established a factory to manufacture raw insulin, a major achievement because there are few factories around the world that have obtained the technology required for the production of insulin.
He highlighted the alternative medicine project being carried out by the company, including components similar to the natural materials produced in the human body, which are being developed and enhanced to guarantee the best medicines to the patients.
The company is exporting medicines to the Latin America countries, New Zealand and the United States, he added.
– By Rajive Singh